LONDON-- September 07, 2022 -- The full results from a year-long study showed that smokers switching exclusively to glo, BAT’s flagship Tobacco Heating Product (THP), achieved significant and sustained improvements in several indicators of potential harm associated with early disease development compared to smokers who continued to smoke. This included lung disease, cancer, and cardiovascular disease (CVD).

The full results, which were published in Internal and Emergency Medicine[i], build upon the favourable changes reported at three and six-months. The improvements observed were sustained over the 12 months of the study, adding to the weight of evidence that supports glo as a less risky[*] alternative for adult smokers who would not otherwise quit.[ii,iii]

Dr David O’Reilly, Director, Scientific Research at BAT, said: “The results from this study are the most important data we have ever generated about glo and for the THP category in general. This real-world study allows us to assess the changes that adult smokers switching exclusively to glo experience, by assessing early indicators of potential harm associated with disease development. It provides much needed new evidence about the size of the change and durability of the effect switching completely to glo can have, and reinforces glo’s potential as a reduced-risk product[*].

“I’d like to thank everyone who participated in and helped deliver this study. It is another important step forward in our journey to building A Better Tomorrow.”

Based on the early indicators of disease measured, smokers who switched completely to glo instead of continuing to smoke showed:

· Significant and sustained reduction in a biomarker with the potential to cause DNA damage associated with lung cancer
· Significant and sustained reduction in white blood cell count, an inflammatory marker associated with early development of CVD and other smoking-related diseases
· Sustained improvement in HDL cholesterol associated with reduced development of CVD
· Significant and sustained improvement in an indicator of lung health (FeNO)
· Significant and sustained improvement in a key indicator of oxidative stress, a process implicated in several smoking-related diseases, such as CVD

These new data build on the findings of another recent publication about glo[iiii], which concluded that “given the accumulated scientific data, glo is a reduced exposure product compared to combustible cigarettes and is reasonably deemed to reduce the risk of smoking-related diseases and supports the conclusion that smokers who switch entirely to THP glo use, will reduce their relative risk of developing smoking-related diseases as compared to continued smoking.”